TherapeuticsMD Inc (TXMD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $21.64M
Last updated: Nov 17, 2026 at 11:00 AM ET
TherapeuticsMD Inc (TXMD) Financials: Revenue, Profit and Cash Flow
TherapeuticsMD reported revenue of $3.02M for the fiscal year ended Dec 31, 2025, up 71.6% from the year before. That year, net income was -$569.00K with a net margin of -18.8%, operating cash flow was $2.45M and free cash flow was $2.45M. The quarter ended Sep 30, 2026 had revenue of $1.26M and net income of $491.00K.
Revenue and Margins
The net margin was -18.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue fell from $19.36M, a compound annual decline of 18.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $3.02M | +71.6% | 100.0% | -145.3% | -18.8% |
| Dec 2024 | $1.76M | +35.3% | 100.0% | -347.1% | -123.9% |
| Dec 2023 | $1.30M | -98.1% | 100.0% | -654.6% | -789.4% |
| Dec 2022 | $69.96M | +2619.1% | 98.0% | 1.7% | 160.1% |
| Dec 2021 | $2.57M | -96.0% | 45.5% | -3092.8% | -6700.9% |
| Dec 2020 | $64.87M | +30.7% | 75.4% | -239.8% | -282.9% |
| Dec 2019 | $49.65M | +208.4% | 87.2% | -304.6% | -354.8% |
| Dec 2018 | $16.10M | -4.0% | 83.0% | -808.8% | -823.7% |
| Dec 2017 | $16.78M | -13.3% | 84.3% | -462.7% | -458.5% |
| Dec 2016 | $19.36M | N/A | 78.4% | -466.3% | -464.3% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income rose 223.0% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02M | $1.76M | $1.30M | $69.96M | $2.57M | $64.87M | $49.65M | $16.10M | $16.78M | $19.36M |
| Cost of revenue | $0 | $0 | $0 | $1.40M | $1.40M | $15.97M | $6.33M | $2.74M | $2.64M | $4.19M |
| Gross profit | $3.02M | $1.76M | $1.30M | $68.57M | $1.17M | $48.90M | $43.31M | $13.36M | $14.14M | $15.17M |
| Research and development | $0 | $0 | $0 | $0 | $0 | $10.43M | $19.79M | $27.30M | $33.85M | $53.94M |
| Operating income | -$4.39M | -$6.11M | -$8.52M | $1.19M | -$79.58M | -$155.54M | -$151.21M | -$130.22M | -$77.63M | -$90.25M |
| Net income | -$569.00K | -$2.18M | -$10.28M | $112.00M | -$172.41M | -$183.52M | -$176.15M | -$132.62M | -$76.93M | -$89.88M |
| EBITDA | $398.00K | -$1.20M | -$6.82M | $2.38M | -$78.57M | -$150.88M | -$147.31M | -$127.38M | -$76.72M | -$89.75M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.26M | $869.00K | $724.00K | $893.00K | $784.00K | $952.00K | $393.00K | $667.00K | $547.00K | $234.00K | $313.00K | $502.00K |
| Gross profit | $1.26M | $869.00K | $724.00K | $893.00K | $784.00K | $952.00K | $393.00K | $667.00K | $547.00K | $234.00K | $313.00K | $502.00K |
| Operating income | -$479.00K | -$816.00K | -$723.00K | -$1.96M | -$862.00K | -$695.00K | -$1.28M | -$1.05M | -$1.13M | -$2.79M | -$1.14M | -$1.61M |
| Net income | $491.00K | $155.00K | $95.00K | -$619.00K | $152.00K | $551.00K | -$653.00K | $252.00K | -$609.00K | -$1.09M | -$734.00K | -$883.00K |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $975.00K by $6.51M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $37.66M | $38.82M | $43.31M | $90.46M | $169.47M | $181.61M | $265.99M | $211.98M | $143.23M | $142.47M |
| Current assets | $14.45M | $12.26M | $11.80M | $55.35M | $119.47M | $128.40M | $208.42M | $186.78M | $139.55M | $139.41M |
| Cash and equivalents | $7.48M | $5.06M | $4.33M | $38.07M | $64.91M | $80.49M | $160.83M | $161.61M | $127.14M | $131.53M |
| Total liabilities | $10.78M | $11.45M | $14.02M | $55.31M | $263.09M | $305.61M | $256.78M | $114.46M | $13.32M | $14.98M |
| Short-term debt | $975.00K | $1.63M | $1.47M | $1.39M | $188.27M | $0 | $1.50M | N/A | N/A | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $237.70M | $194.63M | $73.38M | $0 | $0 |
| Shareholder equity | $26.88M | $27.37M | $29.29M | $35.14M | -$93.62M | -$124.00M | $9.20M | $97.52M | $129.91M | $127.49M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $37.93M | $37.53M | $37.58M | $37.66M | $38.67M | $38.50M | $38.24M | $38.82M | $39.55M | $40.13M | $42.09M | $43.31M |
| Total liabilities | $10.31M | $10.40M | $10.61M | $10.78M | $11.23M | $11.21M | $11.50M | $11.45M | $12.46M | $12.46M | $13.42M | $14.02M |
| Cash and equivalents | $10.45M | $9.19M | $8.42M | $7.48M | $7.12M | $6.07M | $5.75M | $5.06M | $5.05M | $5.23M | $4.34M | $4.33M |
| Shareholder equity | $27.62M | $27.13M | $26.97M | $26.88M | $27.44M | $27.29M | $26.74M | $27.37M | $27.09M | $27.67M | $28.66M | $29.29M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.45M | $1.17M | -$23.08M | $9.36M | -$142.69M | -$159.47M | -$165.72M | -$106.81M | -$76.16M | -$69.14M |
| Capital expenditures | $0 | $0 | $48.14M | $355.00K | $34.00K | $207.00K | $2.45M | $217.04K | $61.82K | $396.15K |
| Free cash flow | $2.45M | $1.17M | -$71.22M | $9.00M | -$142.73M | -$159.68M | -$168.17M | -$107.03M | -$76.22M | -$69.54M |
| Investing cash flow | $0 | $0 | $0 | -$355.00K | -$2.22M | -$1.60M | -$23.89M | -$21.50M | -$827.11K | -$1.26M |
| Financing cash flow | $0 | $0 | $3.15M | -$235.21M | $129.55M | $80.72M | $188.83M | $162.79M | $72.58M | $137.23M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.27M | $787.00K | $936.00K | $375.00K | $999.00K | $394.00K | $686.00K | $17.00K | -$71.00K | $1.45M | -$229.00K | -$4.96M |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $7.84M | $0 |
| Free cash flow | N/A | N/A | $936.00K | $375.00K | $999.00K | $394.00K | $686.00K | $17.00K | -$71.00K | $1.45M | -$8.07M | -$4.96M |
Frequently Asked Questions About TXMD
What is TherapeuticsMD's annual revenue?
TherapeuticsMD reported revenue of $3.02M for the fiscal year ended Dec 31, 2025.
How fast is TherapeuticsMD's revenue growing?
Revenue was up 71.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -64.9%.
Is TherapeuticsMD profitable?
No. TherapeuticsMD reported net income of -$569.00K for the fiscal year ended Dec 31, 2025, with a net margin of -18.8%.
How much free cash flow does TXMD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $2.45M minus capital expenditures of $0 produced free cash flow of $2.45M.
How much debt does TherapeuticsMD have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $975.00K and cash and equivalents of $7.48M.
TXMD pages: Overview, Earnings, Financials, Valuation, Competitors